WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006091009) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER COMPRISING LMH-RA COMPLEX
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/091009    International Application No.:    PCT/KR2006/000600
Publication Date: 31.08.2006 International Filing Date: 22.02.2006
IPC:
A61K 31/07 (2006.01), A61P 35/00 (2006.01)
Applicants: NANOHYBRID CO., LTD. [KR/KR]; 4F., Natural Science B/D-B, Ewha Womans University, 11-1, Daehyun-dong, Seodaemun-gu, Seoul 120-750 (KR) (For All Designated States Except US).
CHOY, Jin-ho [KR/KR]; (KR) (For US Only).
PARK, Taeun [KR/KR]; (KR) (For US Only).
KIM, Sang-tae [KR/KR]; (KR) (For US Only).
SON, You-hwan [KR/KR]; (KR) (For US Only)
Inventors: CHOY, Jin-ho; (KR).
PARK, Taeun; (KR).
KIM, Sang-tae; (KR).
SON, You-hwan; (KR)
Agent: Y.P.LEE, MOCK & PARTNERS; 1575-1 Seocho-dong, Seocho-gu, Seoul 137-875 (KR)
Priority Data:
10-2005-0016168 25.02.2005 KR
Title (EN) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER COMPRISING LMH-RA COMPLEX
(FR) COMPOSITION PHARMACEUTIQUE CONTENANT UN COMPLEXE LMH-RA DESTINEE AU TRAITEMENT DU CANCER
Abstract: front page image
(EN)Provided is a pharmaceutical composition for the treatment of liver cancer, including a layered metal hydroxide-retinoic acid (LMH-RA) hybrid as a novel drug delivery system which shows few side effects of retinoic acid, good drug stability, sustained drug release, and improved drug delivery efficiency.
(FR)La présente invention se rapporte à une composition pharmaceutique destinée au traitement du cancer du foie, qui contient un hybride d'un hydroxyde métallique en couches et de l'acide rétinoïque (LMH-RA) faisant office de nouveau système d'administration de médicament, et présente peu d'effets secondaires de l'acide rétinoïque, une bonne stabilité du médicament, une libération prolongée du médicament et une efficacité améliorée d'administration du médicament.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: Korean (KO)